Comparative in vitro activity of moxifloxacin against Gram-positive clinical isolates

被引:61
作者
Hoogkamp-Korstanje, JAA [1 ]
Roelofs-Willemse, J [1 ]
机构
[1] Catholic Univ Nijmegen, St Radboud Hosp, Dept Med Microbiol, NL-6500 HB Nijmegen, Netherlands
关键词
D O I
10.1093/jac/45.1.31
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The in vitro activity of moxifloxacin was compared with that of 15 antibacterial agents against 513 Gram-positive microorganisms. The MIC90 (mg/L) of moxifloxacin was 0.06 for quinolone-susceptible Staphylococcus aureus and Staphylococcus epidermidis, 0.12 for Streptococcus pyogenes and Streptococcus agalactiae; 0.25 for Streptococcus pneumoniae, Streptococcus mitis, Streptococcus bovis, Streptococcus anginosus and Actinomyces pyogenes; 0.5 for Streptococcus sanguis and Listeria monocytogenes, 2 for Corynebacterium jekeium and Bifidobacterium bivius. Over 50% of Enterococcus faecalis, Enterococcus faecium, quinolone-resistant staphylococci, Nocardia asteroides and Clostridium difficile were susceptible to less than or equal to 2 mg/L moxifloxacin. Moxifloxacin and trovafloxacin demonstrated comparably high activity towards Gram-positive cocci; moxifloxacin and clinafloxacin were most active against Grampositive bacilli.
引用
收藏
页码:31 / 39
页数:9
相关论文
共 9 条
[1]   RAPID DEVELOPMENT OF CIPROFLOXACIN RESISTANCE IN METHICILLIN-SUSCEPTIBLE AND METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS [J].
BLUMBERG, HM ;
RIMLAND, D ;
CARROLL, DJ ;
TERRY, P ;
WACHSMUTH, IK .
JOURNAL OF INFECTIOUS DISEASES, 1991, 163 (06) :1279-1285
[2]   In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against Gram-positive and Gram-negative pathogens from respiratory tract infections [J].
HoogkampKorstanje, JAA .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (03) :427-431
[3]  
*NAT COMM CLIN LAB, 1997, METHODS DILUTION ANT
[4]   NEW QUINOLONES AND GRAM-POSITIVE BACTERIA [J].
PIDDOCK, LJV .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (02) :163-169
[5]   INCREASING RESISTANCE OF ENTEROCOCCI TO CIPROFLOXACIN [J].
SCHABERG, DR ;
DILLON, WI ;
TERPENNING, MS ;
ROBINSON, KA ;
BRADLEY, SF ;
KAUFFMAN, CA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (11) :2533-2535
[6]   In vitro activity of BAY 12-8039, a new fluoroquinolone, against species representative of respiratory tract pathogens [J].
Souli, M ;
Wennersten, CB ;
Eliopoulos, GM .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 1998, 10 (01) :23-30
[7]   Activity of CP 99,219 (trovafloxacin) compared with ciprofloxacin, sparfloxacin, clinafloxacin, lomefloxacin and cefuroxime against ten penicillin-susceptible and pencillin-resistant pneumococci by time-kill methodology [J].
Visalli, MA ;
Jacobs, MR ;
Appelbaum, PC .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1996, 37 (01) :77-84
[8]   Comparative activity of trovafloxacin and Bay 12-8039 against 452 clinical isolates of Streptococcus pneumoniae [J].
Weiss, K ;
Laverdiere, M ;
Restieri, C .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 42 (04) :523-525
[9]   In vitro activity of BAY 12-8039, a new fluoroquinolone [J].
Woodcock, JM ;
Andrews, JM ;
Boswell, FJ ;
Brenwald, NP ;
Wise, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (01) :101-106